SynthesisInternational journal of molecular sciences2024
The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis-A Systematic Review.
Synthesis in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 23 citations in OpenAlex.
- Effects of thoracic manipulation with trigger point therapy on inflammatory cytokine levels in individuals with multiple sclerosis: a pilot study.Frontiers in rehabilitation sciences · 2026Trial
- Role of the WNT signalling pathway in physiological and pathological blood-brain barrier.Annals of medicine · 2026Review
- Selected Cytokines and Matrix Metalloproteinases in Pathogenesis and Treatment of Multiple Sclerosis.International journal of molecular sciences · 2026Review
- Serum Levels of the Proinflammatory Cytokines IL-6, IL-16, IL-18, and IL-36 in Patients with Multiple Sclerosis from the Western Region of Saudi Arabia: Associations with Disease Duration and Disability.Neurology international · 2026Article
- Emerging therapeutic strategies in multiple sclerosis: a focus on innovative and targeted approaches.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Circulating Proinflammatory Cytokines and Soluble Cytokine Receptors as Diagnostic Biomarkers in Multiple Sclerosis.Journal of clinical medicine · 2026Article
- Exploring the Association of Interleukin 13 Polymorphism (rs20541) and Serum Lipocalin 2 with Risk and Disability in Multiple Sclerosis.Journal of inflammation research · 2026Article
- Imbalance of Circulating B-Cell Subsets Was Associated With Higher Risk of Relapses in RRMS Patients.Journal of immunology research · 2026Article
- A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.Frontiers in immunology · 2026Article
- From Demyelination to Intervention: Natural Compounds as Emerging Therapeutic Targets in Multiple Sclerosis Neuroinflammation.Journal of immunology research · 2026Review
- Synergistic myelin regenerative, immunomodulatory and anti-inflammatory effects of vanillin and adipose derived stem cells in cuprizone animal model of multiple sclerosis.Iranian journal of basic medical sciences · 2026Article
- Interleukin in Immune-Mediated Diseases: An Updated Review.Molecular biotechnology · 2025Review
- Altered miR-203a and miR-3622b-5p expressions in multiple sclerosis: novel correlations with apoptotic gene expression profiles.Molecular biology reports · 2025Article
- Acetyl 11-Keto Beta-Boswellic Acid Improves Neurological Functions in a Mouse Model of Multiple Sclerosis.Inflammation · 2025Article
- Association of HLA-DRA, HLA-DQA1, and IL-6 gene variations with susceptibility to multiple sclerosis.Molecular biology reports · 2025Article
- Changes in Concentration of Selected Biomarkers of Exposure in Users of Classic Cigarettes, E-Cigarettes, and Heated Tobacco Products-A Narrative Review.International journal of molecular sciences · 2025Review
- Does Clostridium Perfringens Epsilon Toxin Mimic an Auto-Antigen Involved in Multiple Sclerosis?Toxins · 2025Observational
- The role of regulatory T cells in central nervous system diseases in dogs: fighting with a double-edged sword toward translational discoveries.American journal of translational research · 2025Review
- IL-4 and IL-13 in Cardiovascular Disease: From Immune Modulation to Therapeutic Possibilities - A Narrative Review.Journal of inflammation research · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis is a disabling inflammatory disorder of the central nervous system characterized by demyelination and neurodegeneration. Given that multiple sclerosis remains an incurable disease, the management of MS predominantly focuses on reducing relapses and decelerating the progression of both physical and cognitive decline. The continuous autoimmune process modulated by cytokines seems to be a vital contributing factor to the development and relapse of multiple sclerosis. This review sought to summarize the role of selected interleukins in the pathogenesis and advancement of MS. Patients with MS in the active disease phase seem to exhibit an increased serum level of IL-2, IL-4, IL-6, IL-13, IL-17, IL-21, IL-22 and IL-33 compared to healthy controls and patients in remission, while IL-10 appears to have a beneficial impact in preventing the progression of the disease. Despite being usually associated with proinflammatory activity, several studies have additionally recognized a neuroprotective role of IL-13, IL-22 and IL-33. Moreover, selected gene polymorphisms of IL-2R, IL-4, IL-6, IL-13 and IL-22 were identified as a possible risk factor related to MS development. Treatment strategies of multiple sclerosis that either target or utilize these cytokines seem rather promising, but more comprehensive research is necessary to gain a clearer understanding of how these cytokines precisely affect MS development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.